Clinical Research Directory

Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Males and females age \>= 18 years on day of consent * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Patients undergoing resection for biopsy proven colon adenocarcinoma * Medically fit for colon resection * Ability to complete required study questionnaires * Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: * Diagnosis of rectal adenocarcinoma * Simultaneously enrolled in any therapeutic clinical trial. Subsequent enrollment in an adjuvant therapy clinical trial is not automatically prohibited by this trial. Trial eligibility for subsequent studies will be determined by the VIVA principal investigator (PI) and the PI of the other clinical trial in question * Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements * Active grade 3 (per the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment * Prisoner status * Allergies to eggs, egg products, soybeans, or soy products (relative or absolute contraindication to propofol) * Personal or first degree relative with a history of malignant hyperthermia (absolute contraindication to inhaled volatile anesthetics) * Diagnosis of inflammatory bowel disease * Planned multi-visceral resection (examples include: pelvic exenteration, combined liver and colon resection) * Patients undergoing resection for unresectable polyps, or incomplete polypectomies without biopsy proven adenocarcinoma are excluded